Global Hepatic
Encephalopathy Market, by Drug Class (Antibiotics, Laxatives, L-ornithine
L-aspartate, and Others), by Route of Administration (Oral, Intravenous, and
Rectal), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and
Online Pharmacies), and by Region (North America, Latin America, Europe, Asia
Pacific, Middle East, and Africa), is estimated to be valued at US$ 355.4
million in 2020 and is estimated to exhibit a CAGR of 5.3% during the forecast
period (2020-2027).
The increasing prevalence of
various risk factors such as hepatitis C, hepatic cirrhosis among the
population is expected to drive the global hepatic encephalopathy market growth
over the forecast period. For instance, according to the CMAJ Open journal:
2018, prevalence of liver cirrhosis is expected to increase due to the rising
cases of hepatitis C and the non-alcoholic fatty liver disease among the
Canadian population. Around 30% of people in Canada suffered from liver
diseases.
Market players are indulged in
inorganic activities such as acquisitions, which is expected to expand the
product portfolio as well as strengthen the position of the companies in the
global market. For instance, in 2018, Ferring Pharmaceuticals Inc. acquired
Rebiotix Inc, a clinical stage biotechnology company. This acquisition bought
together two innovative healthcare companies that focus on exploring and
understanding the human microbiome for developing new solutions for patients.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2596
Global Hepatic Encephalopathy
Market– Impact of Coronavirus (COVID – 19) Pandemic
The COVID-19 pandemic is expected
to restrain growth of the global hepatic encephalopathy market over the
forecast period. According to National center for Biotechnology Information
(NCBI), 29th September 2020, the hepatic encephalopathy treatment is required
for majority of patients suffering with severe liver damage and the treatment
might be delayed due to the pandemic. Although, during the COVID-19 pandemic,
the treatment of severe liver damage patients is postponed or even cancelled
due to the unavailability of antibiotics, laxatives, and other medications and
irregular supply and transportation of drugs.
Furthermore, according to the U.S
Food and Drug Administration (FDA), 18th September 2020, the COVID-19 pandemic
has disrupted the global drug supply due to government-mandated or recommended
temporary shutdowns, safety initiatives to ensure employee health and
well-being, insufficient labor force, and restrictions on import and export
activities, and travel. Antibiotic manufacturing has been particularly
affected.
Browse 38 Market Data Tables and
27 Figures spread through 149 Pages and in-depth TOC on, Global Hepatic
Encephalopathy Market, by Drug Class (Antibiotics, Laxatives, L-ornithine L-aspartate,
and Others), by Route of Administration (Oral, Intravenous, and Rectal), by
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online
Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific,
Middle East, and Africa).
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/hepatic-encephalopathy-market-2596
Key players are majorly focused
on conducting clinical trials for development of new drugs for hepatic
encephalopathy, which is expected to drive growth of the global hepatic
encephalopathy market over the forecast period. For instance, in 2019,
Mallinckrodt Pharmaceuticals conducted clinical trials for MNK-6105 (ornithine
phenylacetate) intravenous and MNK-6106 (ornithine phenylacetate) oral
medications for preventing the recurrence of chronic hepatic encephalopathy.
The trial is currently in phase III of the trials.
Key Takeaways of the Hepatic Encephalopathy
Market:
The global hepatic encephalopathy
market is expected to exhibit a CAGR of 5.3% over the forecast period
(2020-2027), owing to growth in potential markets, especially in Europe. North
America accounted for major market share.
The increasing distribution of
lactulose for treatment of hepatic encephalopathy is expected to drive growth
of the global hepatic encephalopathy market over the forecast period. For
instance, in April 2017, Cumberland Pharmaceuticals, a U.S.-based specialty
pharmaceutical company, and Poly Pharmaceuticals Inc., a privately-held
U.S.-based specialty pharmaceutical company signed an agreement for
co-promoting the Kristalose (lactulose solution for treatment of hepatic
encephalopathy), which is developed by Poly Pharmaceuticals Inc., within the
U.S. This multi-year co-promotion partnership will expand current sales for
Kristalose across the U.S.
Some of the major players
operating in the global hepatic encephalopathy market include ASKA
Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido
Biosciences, Kannalife Sciences, Inc., Bausch Health Companies Inc., Ferring
Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB,
Norgine B.V., Abbott Laboratories, and QR Science and Technology Development
Co. Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2596
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment